The epidemiology of superficial Streptococcal A (impetigo and pharyngitis) infections in Australia: A systematic review.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 16 10 2022
accepted: 09 06 2023
medline: 4 12 2023
pubmed: 30 11 2023
entrez: 30 11 2023
Statut: epublish

Résumé

Streptoccocal A (Strep A, GAS) infections in Australia are responsible for significant morbidity and mortality through both invasive (iGAS) and post-streptococcal (postGAS) diseases as well as preceding superficial (sGAS) skin and throat infection. The burden of iGAS and postGAS are addressed in some jurisdictions by mandatory notification systems; in contrast, the burden of preceding sGAS has no reporting structure, and is less well defined. This review provides valuable, contemporaneous evidence on the epidemiology of sGAS presentations in Australia, informing preventative health projects such as a Streptococcal A vaccine and standardisation of primary care notification. MEDLINE, Scopus, EMBASE, Web of Science, Global Health, Cochrane, CINAHL databases and the grey literature were searched for studies from an Australian setting relating to the epidemiology of sGAS infections between 1970 and 2020 inclusive. Extracted data were pooled for relevant population and subgroup analysis. From 5157 titles in the databases combined with 186 grey literature reports and following removal of duplicates, 4889 articles underwent preliminary title screening. The abstract of 519 articles were reviewed with 162 articles identified for full text review, and 38 articles identified for inclusion. The majority of data was collected for impetigo in Aboriginal and Torres Strait Islander populations, remote communities, and in the Northern Territory, Australia. A paucity of data was noted for Aboriginal and Torres Strait Islander people living in urban centres or with pharyngitis. Prevalence estimates have not significantly changed over time. Community estimates of impetigo point prevalence ranged from 5.5-66.1%, with a pooled prevalence of 27.9% [95% CI: 20.0-36.5%]. All studies excepting one included >80% Aboriginal and Torres Strait Islander people and all excepting two were in remote or very remote settings. Observed prevalence of impetigo as diagnosed in healthcare encounters was lower, with a pooled estimate of 10.6% [95% CI: 3.1-21.8%], and a range of 0.1-50.0%. Community prevalence estimates for pharyngitis ranged from 0.2-39.4%, with a pooled estimate of 12.5% [95% CI: 3.5-25.9%], higher than the prevalence of pharyngitis in healthcare encounters; ranging from 1.0-5.0%, and a pooled estimate of 2.0% [95% CI: 1.3-2.8%]. The review was limited by heterogeneity in study design and lack of comparator studies for some populations. Superficial Streptococcal A infections contribute to an inequitable burden of disease in Australia and persists despite public health interventions. The burden in community studies is generally higher than in health-services settings, suggesting under-recognition, possible normalisation and missed opportunities for treatment to prevent postGAS. The available, reported epidemiology is heterogeneous. Standardised nation-wide notification for sGAS disease surveillance must be considered in combination with the development of a Communicable Diseases Network of Australia (CDNA) Series of National Guideline (SoNG), to accurately define and address disease burden across populations in Australia. This review is registered with PROSPERO. Registration number: CRD42019140440.

Sections du résumé

BACKGROUND BACKGROUND
Streptoccocal A (Strep A, GAS) infections in Australia are responsible for significant morbidity and mortality through both invasive (iGAS) and post-streptococcal (postGAS) diseases as well as preceding superficial (sGAS) skin and throat infection. The burden of iGAS and postGAS are addressed in some jurisdictions by mandatory notification systems; in contrast, the burden of preceding sGAS has no reporting structure, and is less well defined. This review provides valuable, contemporaneous evidence on the epidemiology of sGAS presentations in Australia, informing preventative health projects such as a Streptococcal A vaccine and standardisation of primary care notification.
METHODS AND FINDINGS RESULTS
MEDLINE, Scopus, EMBASE, Web of Science, Global Health, Cochrane, CINAHL databases and the grey literature were searched for studies from an Australian setting relating to the epidemiology of sGAS infections between 1970 and 2020 inclusive. Extracted data were pooled for relevant population and subgroup analysis. From 5157 titles in the databases combined with 186 grey literature reports and following removal of duplicates, 4889 articles underwent preliminary title screening. The abstract of 519 articles were reviewed with 162 articles identified for full text review, and 38 articles identified for inclusion. The majority of data was collected for impetigo in Aboriginal and Torres Strait Islander populations, remote communities, and in the Northern Territory, Australia. A paucity of data was noted for Aboriginal and Torres Strait Islander people living in urban centres or with pharyngitis. Prevalence estimates have not significantly changed over time. Community estimates of impetigo point prevalence ranged from 5.5-66.1%, with a pooled prevalence of 27.9% [95% CI: 20.0-36.5%]. All studies excepting one included >80% Aboriginal and Torres Strait Islander people and all excepting two were in remote or very remote settings. Observed prevalence of impetigo as diagnosed in healthcare encounters was lower, with a pooled estimate of 10.6% [95% CI: 3.1-21.8%], and a range of 0.1-50.0%. Community prevalence estimates for pharyngitis ranged from 0.2-39.4%, with a pooled estimate of 12.5% [95% CI: 3.5-25.9%], higher than the prevalence of pharyngitis in healthcare encounters; ranging from 1.0-5.0%, and a pooled estimate of 2.0% [95% CI: 1.3-2.8%]. The review was limited by heterogeneity in study design and lack of comparator studies for some populations.
CONCLUSIONS CONCLUSIONS
Superficial Streptococcal A infections contribute to an inequitable burden of disease in Australia and persists despite public health interventions. The burden in community studies is generally higher than in health-services settings, suggesting under-recognition, possible normalisation and missed opportunities for treatment to prevent postGAS. The available, reported epidemiology is heterogeneous. Standardised nation-wide notification for sGAS disease surveillance must be considered in combination with the development of a Communicable Diseases Network of Australia (CDNA) Series of National Guideline (SoNG), to accurately define and address disease burden across populations in Australia.
TRIAL REGISTRATION BACKGROUND
This review is registered with PROSPERO. Registration number: CRD42019140440.

Identifiants

pubmed: 38033025
doi: 10.1371/journal.pone.0288016
pii: PONE-D-22-28601
pmc: PMC10688633
doi:

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0288016

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright: © 2023 Wiegele et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pediatr Infect Dis J. 1997 May;16(5):494-9
pubmed: 9154544
BMC Cardiovasc Disord. 2005 May 31;5(1):11
pubmed: 15927077
Educ Prim Care. 2014 May;25(3):140-8
pubmed: 25198470
Med J Aust. 2016 Sep 5;205(5):201-3
pubmed: 27581260
BMC Public Health. 2015 Jul 23;15:696
pubmed: 26202429
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Aust Fam Physician. 1995 Apr;24(4):625-9, 632
pubmed: 7771970
Pediatr Infect Dis J. 2002 May;21(5):375-80
pubmed: 12150171
Int J Pediatr Otorhinolaryngol. 2016 Jul;86:224-32
pubmed: 27260611
J Paediatr Child Health. 1995 Dec;31(6):563
pubmed: 8924314
Med J Aust. 2021 Mar;214(5):220-227
pubmed: 33190309
PLoS One. 2020 Nov 18;15(11):e0242107
pubmed: 33206687
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet Infect Dis. 2015 Aug;15(8):960-7
pubmed: 26088526
Med J Aust. 1992 Apr 20;156(8):537-40
pubmed: 1565046
Curr Top Microbiol Immunol. 2013;368:1-27
pubmed: 23242849
J Paediatr Child Health. 1995 Jun;31(3):245-8
pubmed: 7669388
Pediatr Infect Dis J. 2016 Apr;35(4):374-8
pubmed: 26599569
Clin Evid. 2004 Dec;(12):2079-87
pubmed: 15865772
Med J Aust. 2001 Oct 1;175(7):367-70
pubmed: 11700814
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Med J Aust. 2017 Jul 3;207(1):37-38
pubmed: 28659114
Clin Infect Dis. 2019 Aug 16;69(5):877-883
pubmed: 30624673
Aust N Z J Public Health. 1997 Apr;21(2):121-6
pubmed: 9161065
BMJ. 2003 Aug 23;327(7412):415-9
pubmed: 12933727
PLoS One. 2021 Aug 11;16(8):e0255789
pubmed: 34379660
Lancet. 2014 Dec 13;384(9960):2132-40
pubmed: 25172376
PLoS One. 2017 Nov 30;12(11):e0188803
pubmed: 29190667
Aust J Gen Pract. 2021 May;50(5):265-269
pubmed: 33928273
Med J Aust. 2020 Mar;212(5):231-237
pubmed: 31630410
Med J Aust. 1976 Oct 2;2(SP1):15-23
pubmed: 994888
Med J Aust. 1992 Oct 19;157(8):521-2
pubmed: 1479971
Emerg Med Int. 2014;2014:463026
pubmed: 24800080
BMC Pediatr. 2017 Nov 22;17(1):195
pubmed: 29166891
Australas J Dermatol. 2011 Nov;52(4):270-3
pubmed: 22070701
BMC Public Health. 2019 Dec 30;19(1):1750
pubmed: 31888568
Med J Aust. 2020 Nov;213 Suppl 10:S3-S31
pubmed: 33190287
Health Res Policy Syst. 2009 Nov 20;7:25
pubmed: 19925681
Med J Aust. 2004 Mar 1;180(5):216-9
pubmed: 14984340
PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005726
pubmed: 28671945
Pediatrics. 2007 Nov;120(5):950-7
pubmed: 17974731
Aust J Rural Health. 2005 Oct;13(5):282-9
pubmed: 16171502
PLoS One. 2015 Aug 28;10(8):e0136789
pubmed: 26317533
Int J Environ Res Public Health. 2020 Jan 28;17(3):
pubmed: 32012972
Am J Trop Med Hyg. 2018 Dec;99(6):1643-1648
pubmed: 30398135
Intern Med J. 2021 Jun;51(6):835-844
pubmed: 32372512
PLoS One. 2018 Sep 17;13(9):e0203684
pubmed: 30222765
Heart Lung Circ. 2007 Aug;16(4):254-9
pubmed: 17581789
BMC Infect Dis. 2014 Dec 31;14:727
pubmed: 25551178
J Paediatr Child Health. 2010 Mar;46(3):131-3
pubmed: 20415992
Clin Infect Dis. 2006 Sep 15;43(6):683-9
pubmed: 16912939
PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006335
pubmed: 29554121
PLoS One. 2013;8(3):e58231
pubmed: 23469270
Int J Environ Health Res. 2001 Nov;11(4):291-8
pubmed: 11798416
Vaccine. 2018 Nov 12;36(46):6968-6978
pubmed: 30340879
Aust Health Rev. 2008 Nov;32(4):691-9
pubmed: 18980565
BMJ Open. 2022 Mar 10;12(3):e056239
pubmed: 35273057
Bull World Health Organ. 2008 Apr;86(4):275-81
pubmed: 18438516
Int J Environ Res Public Health. 2020 Feb 19;17(4):
pubmed: 32093099
Med J Aust. 2003 Jan 20;178(2):56-60
pubmed: 12526722
PLoS Negl Trop Dis. 2009 Nov 24;3(11):e554
pubmed: 19936297
Med J Aust. 1971 Sep 4;2(10):521-3
pubmed: 5120445

Auteurs

Sophie Wiegele (S)

Perth Children's Hospital, Nedlands, Western Australia, Australia.
Telethon Kids Institute, Nedlands, Western Australia, Australia.

Elizabeth McKinnon (E)

Telethon Kids Institute, Nedlands, Western Australia, Australia.

Bede van Schaijik (B)

University of Western Australia, Perth, Western Australia, Australia.

Stephanie Enkel (S)

Telethon Kids Institute, Nedlands, Western Australia, Australia.
University of Western Australia, Perth, Western Australia, Australia.

Katharine Noonan (K)

Telethon Kids Institute, Nedlands, Western Australia, Australia.

Asha C Bowen (AC)

Perth Children's Hospital, Nedlands, Western Australia, Australia.
Telethon Kids Institute, Nedlands, Western Australia, Australia.
University of Western Australia, Perth, Western Australia, Australia.

Rosemary Wyber (R)

Telethon Kids Institute, Nedlands, Western Australia, Australia.
University of Western Australia, Perth, Western Australia, Australia.
National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH